CeriBell Inc

CBLL

Market cap $439M

Accomplished innovator and healthcare executive brings proven strategic leadership and expertise in scaling high-growth healthcare companies Accomplished innovator and healthcare executive brings proven strategic leadership and expertise in scaling high-growth healthcare companies

CeriBell (CBLL) Q2 Revenue Jumps 38%

CeriBell, Inc. (NASDAQ:CBLL ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Scott Blumberg - Chief Financial Officer Xingjuan Chao - Co-Founder, President, CEO & Director Conference Call Participants Brandon Vazquez - William Blair & Company L.L.C., Research Division Jeffrey Scott Cohen - Ladenburg Thalmann & Co. Inc., Research Division Joshua Thomas Jennings - TD Cowen, Research Division Marie Yoko Thibault - BTIG, LLC, Research Division Robert Justin Marcus - JPMorgan Chase & Co, Research Division Travis Lee Steed - BofA Securities, Research Division William John Plovanic - Canaccord Genuity Corp., Research Division Brian Johnston - Gilmartin Group LLC Operator Ladies and gentlemen, thank you for standing by.

SUNNYVALE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended June 30, 2025.

SUNNYVALE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the second quarter of 2025 after the close of trading on Tuesday, August 5, 2025.

Complaints Assert Infringement of Patents Related to Point-of-Care Electroencephalography (EEG) Technology Complaints Assert Infringement of Patents Related to Point-of-Care Electroencephalography (EEG) Technology

SUNNYVALE, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 45th Annual Growth Stock Conference. The presentation will take place on Tuesday, June 3, 2025, at 7:20 a.m. Pacific Standard Time / 9:20 a.m. Central Standard Time.

CeriBell, Inc. (NASDAQ:CBLL ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Xingjuan Chao - Co-Founder and Chief Executive Officer Scott Blumberg - Chief Financial Officer Conference Call Participants Stephanie Piazzola - Bank of America Margaret Andrew - William Blair Josh Jennings - TD Cowen John Young - Canaccord Jeffrey Cohen - Ladenburg Thalmann Operator Hello, and thank you for standing by. At this time, I would like to welcome you to the CeriBell Q1 2025 Earnings Call.

SUNNYVALE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended March 31, 2025.

SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Bank of America Securities 2025 Health Care Conference. The presentation will take place on Wednesday, May 14, 2025, at 10:55 a.m. Pacific Standard Time / 1:55 p.m. Eastern Standard Time.